Teva Rejected by U.S. High Court Justice on Copaxone Patent
This article is for subscribers only.
A U.S. Supreme Court justice refused to block a ruling that would open Teva Pharmaceutical Industries Ltd.’s Copaxone multiple-sclerosis drug to generic competition in May.
The lower court ruling invalidated one of the company’s patents and shaved more than a year off the legal protection for Copaxone, a treatment that generated $2.25 billion in U.S. sales for Teva in 2011. Chief Justice John Roberts today rejected Teva’s request to put that ruling on hold while the court decides whether to take up Teva’s appeal.